Acute Pulmonary Thromboembolism in a Patient taking Dabigatran: The Case Report of Possible Dabigatran Resistance

Abstract

Direct oral anticoagulants (DOACs) like dabigatran are new generation of oral anticoagulants, for the prevention and treatment of acute and chronic thromboembolic diseases. The pharmacokinetics of dabigatran is predictable. Dabigatran does not require routine monitoring which make it more convenient alternative to warfarin to reduce the risk of systemic embolism and its resistance has been reported rarely in the literature. We report a case of probable dabigatran resistance here.